LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New ELISA-Based COVID-19 Test Detects and Ranks SARS-CoV-2 Neutralizing Antibodies by Their Potency

By LabMedica International staff writers
Posted on 04 Dec 2020
Print article
Illustration
Illustration
A new enzyme-linked immunosorbent assay (ELISA)-based COVID-19 diagnostic test detects and ranks SARS-CoV-2 neutralizing antibodies by their potency in a simple and relatively short test time.

The test developed internally by AXIM Biotechnologies, Inc. (San Diego, CA, USA) aims to fulfill the need to know the levels of neutralizing antibodies in longitudinal studies of vaccine response in the post-vaccine COVID-19 fight. AXIM’s own reagents and proteins are used in the test kits. The company has completed live SARS-CoV-2 virus microneutralization tests at a Biosafety Level (BSL-3) laboratory with samples from COVID-19 patients to validate diagnostic tests per current Food and Drug Administration (FDA) guidelines. AXIM intends to file its third Emergency Use Authorization (EUA) with the FDA soon.

“From the onset of the pandemic, our scientists have dedicated themselves to creating solutions focused on neutralizing antibody detection. Since no one knows how long vaccines will provide immunity, we continue our development of neutralizing antibody COVID-19 tests,” said AXIM Biotech CEO John W. Huemoeller II. “With the addition of our ELISA-based neutralizing antibody diagnostic test, AXIM hopes to help simplify the testing process for determining a vaccine’s efficacy through clinics across the world.”

“Unlike few currently available ELISA, our uniquely designed assay offers a simple and relatively short test time to detect and rank SARS-CoV-2 neutralizing antibodies by their potency. We believe it will help to evaluate the immune status of patients who recovered from COVID-19 or to monitor immunization efficiency more accurately than other ELISAs,” said AXIM Biotech Chief Technology Officer Alim Seit-Nebi, Ph.D.

Related Links:
AXIM Biotechnologies, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more